Sign in

    Oliver McCammon • LifeSci Capital

    Oliver McCammon is an Equity Analyst at LifeSci Capital specializing in biotechnology and healthcare equity research, with coverage including companies such as Monte Rosa Therapeutics, Aura Biosciences, Celcuity, and Corbus Pharmaceuticals. Over the past year, his performance metrics show a TipRanks success rate of 33.3% and an average return of -14.6%, though platform rankings note a previous 100% success rate from a limited number of ratings and strong returns on select calls. McCammon joined LifeSci Capital before August 2024, with no publicly listed prior analyst roles found, and he regularly issues buy ratings and detailed target prices for emerging biotech firms. Specific professional credentials or FINRA securities licenses are not disclosed in public filings, and no major industry awards or recognitions are listed as of August 2025.

    Oliver McCammon's questions to Celcuity Inc (CELC) leadership

    Oliver McCammon's questions to Celcuity Inc (CELC) leadership • Q1 2025

    Question

    Oliver McCammon of LifeSci Capital asked for a review of the proof-of-concept data for targeting the PI3K/AKT/mTOR pathway in prostate cancer, the potential advantage of multi-node inhibition, and whether PSA data would be included in the upcoming Q2 update.

    Answer

    CEO Brian Sullivan reviewed data from AKT inhibitors in prostate cancer, noting their efficacy in P10-mutated patients. He contrasted this with nonclinical data showing gedatolisib's potency is independent of P10 status and significantly greater than single-node inhibitors, providing a strong rationale for the trial. Sullivan clarified that the upcoming Q2 update will focus on the primary analysis and safety data, with other data, such as PSA levels, to be presented at a future medical meeting.

    Ask Fintool Equity Research AI

    Oliver McCammon's questions to Celcuity Inc (CELC) leadership • Q4 2024

    Question

    Oliver McCammon of LifeSci Capital asked for guidance on how to contextualize the upcoming VIKTORIA-1 data, specifically regarding patient baseline characteristics like measurable disease in competitor studies.

    Answer

    CEO Brian Sullivan explained that heterogeneous study populations can make data interpretation difficult. He emphasized that while median PFS is important, the hazard ratio is a more objective benchmark for comparing results across studies with different patient populations, as it helps factor out some of these differences.

    Ask Fintool Equity Research AI